Fukami T - Search Results

1

Knockdown of superoxide dismutase 2 enhances acetaminophen-induced hepatotoxicity in rat.

Yoshikawa Y, Morita M, Hosomi H, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. Yoshikawa Y, et al. Among authors: fukami t. Toxicology. 2009 Oct 1;264(1-2):89-95. doi: 10.1016/j.tox.2009.07.017. Epub 2009 Jul 30. Toxicology. 2009. PMID: 19647030

2

Novel human CYP2A6 alleles confound gene deletion analysis.

Nakajima M, Yoshida R, Fukami T, McLeod HL, Yokoi T. Nakajima M, et al. Among authors: fukami t. FEBS Lett. 2004 Jul 2;569(1-3):75-81. doi: 10.1016/j.febslet.2004.05.053. FEBS Lett. 2004. PMID: 15225612 Free article.

3

Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.

Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M, Yokoi T. Yamanaka H, et al. Among authors: fukami t. Eur J Pharm Sci. 2004 Aug;22(5):419-25. doi: 10.1016/j.ejps.2004.04.012. Eur J Pharm Sci. 2004. PMID: 15265511

4

A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.

Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, McLeod HL, Yokoi T. Fukami T, et al. Clin Pharmacol Ther. 2004 Dec;76(6):519-27. doi: 10.1016/j.clpt.2004.08.014. Clin Pharmacol Ther. 2004. PMID: 15592323

5

Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.

Fukami T, Nakajima M, Higashi E, Yamanaka H, Sakai H, McLeod HL, Yokoi T. Fukami T, et al. Drug Metab Dispos. 2005 Aug;33(8):1202-10. doi: 10.1124/dmd.105.004994. Epub 2005 May 17. Drug Metab Dispos. 2005. PMID: 15900015 Clinical Trial.

6

A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity.

Fukami T, Nakajima M, Higashi E, Yamanaka H, McLeod HL, Yokoi T. Fukami T, et al. Biochem Pharmacol. 2005 Sep 1;70(5):801-8. doi: 10.1016/j.bcp.2005.05.029. Biochem Pharmacol. 2005. PMID: 15993850

7

CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions.

Yamanaka H, Nakajima M, Fukami T, Sakai H, Nakamura A, Katoh M, Takamiya M, Aoki Y, Yokoi T. Yamanaka H, et al. Among authors: fukami t. Drug Metab Dispos. 2005 Dec;33(12):1811-8. doi: 10.1124/dmd.105.006254. Epub 2005 Aug 31. Drug Metab Dispos. 2005. PMID: 16135656

8

Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6.

Nakajima M, Itoh M, Yamanaka H, Fukami T, Tokudome S, Yamamoto Y, Yamamoto H, Yokoi T. Nakajima M, et al. Among authors: fukami t. J Clin Pharmacol. 2006 Mar;46(3):337-44. doi: 10.1177/0091270005285199. J Clin Pharmacol. 2006. PMID: 16490810

9

CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.

Fukami T, Nakajima M, Sakai H, McLeod HL, Yokoi T. Fukami T, et al. Pharmacogenomics J. 2006 Nov-Dec;6(6):401-12. doi: 10.1038/sj.tpj.6500390. Epub 2006 Apr 25. Pharmacogenomics J. 2006. PMID: 16636685

10

Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.

Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon JT, McLeod HL, Yokoi T. Nakajima M, et al. Among authors: fukami t. Clin Pharmacol Ther. 2006 Sep;80(3):282-97. doi: 10.1016/j.clpt.2006.05.012. Clin Pharmacol Ther. 2006. PMID: 16952495 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

662 results

Search Page

Filters